C4 Therapeutics Management
Management criteria checks 2/4
C4 Therapeutics' CEO is Andrew Hirsch, appointed in Sep 2020, has a tenure of 4.17 years. total yearly compensation is $3.79M, comprised of 16.9% salary and 83.1% bonuses, including company stock and options. directly owns 0.081% of the company’s shares, worth $229.62K. The average tenure of the management team and the board of directors is 3.8 years and 7.3 years respectively.
Key information
Andrew Hirsch
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 16.9% |
| CEO tenure | 4.2yrs |
| CEO ownership | 0.08% |
| Management average tenure | 3.8yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk
Nov 15
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Nov 06We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate
Oct 02Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher
Aug 09C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up
Aug 03Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)
May 12C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$4m | US$639k | -US$132m |
| Sep 30 2023 | n/a | n/a | -US$135m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$131m |
| Dec 31 2022 | US$3m | US$614k | -US$128m |
| Sep 30 2022 | n/a | n/a | -US$107m |
| Jun 30 2022 | n/a | n/a | -US$99m |
| Mar 31 2022 | n/a | n/a | -US$95m |
| Dec 31 2021 | US$952k | US$580k | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$80m |
| Jun 30 2021 | n/a | n/a | -US$82m |
| Mar 31 2021 | n/a | n/a | -US$73m |
| Dec 31 2020 | US$21m | US$168k | -US$66m |
Compensation vs Market: Andrew's total compensation ($USD3.79M) is above average for companies of similar size in the US market ($USD1.47M).
Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.
CEO
Andrew Hirsch (53 yo)
4.2yrs
Tenure
US$3,790,099
Compensation
Mr. Andrew J. Hirsch, M.B.A., is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeuti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$3.79m | 0.081% $ 229.6k | |
| Co-Founder | no data | US$111.41k | 0.45% $ 1.3m | |
| Chief Medical Officer | 1.3yrs | US$1.96m | 0.013% $ 36.6k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| CFO & Treasurer | 1.2yrs | no data | 0.025% $ 71.1k | |
| Chief Accounting Officer | 1.2yrs | no data | 0.0021% $ 6.0k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Senior Manager of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 4.3yrs | US$3.38m | 0.020% $ 56.9k | |
| Chief People Officer | 3.8yrs | no data | 0.020% $ 56.9k | |
| Senior Vice President of Strategic Alliances & Business Development | 8.7yrs | no data | no data | |
| Senior Vice President of Chemistry | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
52yo
Average Age
Experienced Management: CCCC's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.1yrs | US$3.79m | 0.081% $ 229.6k | |
| Co-Founder | 8.9yrs | US$111.41k | 0.45% $ 1.3m | |
| Co-Founder & Member of Scientific Advisory Board | 8yrs | no data | no data | |
| Lead Independent Director | 8.9yrs | US$157.91k | 0.69% $ 2.0m | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Independent Chairman | less than a year | no data | no data | |
| Member of Scientific Advisory Board | 5.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Independent Director | 2.7yrs | US$126.41k | 0.0080% $ 22.7k | |
| Member of Clinical Advisory Board | no data | no data | no data |
7.3yrs
Average Tenure
57yo
Average Age
Experienced Board: CCCC's board of directors are considered experienced (7.3 years average tenure).